On Monday, the FDA approved the use of a new Alzheimer’s drug called aducanumab, developed by the pharmaceutical company Biogen. Whether the drug works remains contested, and the approval decision has set off a fierce debate over the ways that commerce and advocacy might influence which drugs reach market.
↧